Bluejay Diagnostics, Inc. (BJDX)

US — Healthcare Sector
Peers: BBLG  TLIS  NUWE  HSCS  TIVC    NXL  INVO  MOTS  IRIX 

Automate Your Wheel Strategy on BJDX

With Tiblio's Option Bot, you can configure your own wheel strategy including BJDX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BJDX
  • Rev/Share 0.39
  • Book/Share 6.9789
  • PB 0.2235
  • Debt/Equity 0.0485
  • CurrentRatio 2.713
  • ROIC -1.6326

 

  • MktCap 2330924.0
  • FreeCF/Share -12.1203
  • PFCF -0.3471
  • PE -0.1191
  • Debt/Assets 0.0355
  • DivYield 0
  • ROE -1.1423

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 5
  • P/B Score 4
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

About Bluejay Diagnostics, Inc. (BJDX)

  • IPO Date 2021-11-10
  • Website https://www.bluejaydx.com
  • Industry Medical - Devices
  • CEO Mr. Indranil Dey
  • Employees 7

Bluejay Diagnostics, Inc., a diagnostic company, develops and markets patient products for triage, diagnosis, and monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony Fluorescence Immuno-analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge Library, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. In addition, it develops biomarkers for detection of other diseases such as hsTNT/I for myocardial injury and NT-proBNP for cardiac heart failure. It has a license and supply agreement with Toray Industries, Inc. for making and distributing the protein detection chips. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.